Triglycerides and coronary risk in women and the elderly

Archives of Internal Medicine

Volumn 157, Issue 9, 1997, Pages 961-968

  LaRosa, John C ^a,b,c,d  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DIET THERAPY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MACROPHAGE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030964475     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.9.961     Document Type: Review

References (65)

1. Criqui M, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-1225.
2. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
3. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med. 1996;124:518-531.
4. LaRosa JC. Does reducing cholesterol improve CAD survival? Patient Care. 1996;30:61-74.
5. NIH Consensus Conference. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA. 1993;269:505-510.
6. LaRosa JC. Lipoproteins: Their Role in Atherosclerosis and Its Prevention. Needham Heights, Mass: Damon Clinical Laboratories, Damon Corp; 1990.
7. Lewis GF, Steiner G. Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in noninsulin-dependent diabetes mellitus. Diabetes Metab Rev. 1996;12:37-56.
8. Hypertriglyceridaemia and vascular risk. Lancet. 1993;342:781-787.
9. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Arch Intern Med. 1992;152:28-34.
10. Patsch W, Gotto AM Jr. High-density lipoprotein cholesterol, plasma triglyceride, and coronary heart disease: pathophysiology and management. Adv Pharmacol. 1995;32:375-426.
11. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol. 1994;5:395-405.
12. Assman G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol. 1992;8:99-103.
13. Simons L. Triglyceride levels and the risk of coronary artery disease: a view from Australia. Am J Cardiol. 1992;70(suppl):14H-18H.
14. Ebenbichler CF, Kirchmair R, Egger C, Patsch JR. Postprandial state and atherosclerosis. Curr Opin Lipidol. 1995;6:286-290.
15. Karpe F, Steiner G, Uffelman K, et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83-97.
16. Zitoun D, Bara L, Basdevant A, Samama MM. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler Thromb Vasc Biol. 1996;16:77-81.
17. Humphries S, Lane A, Green F, et al. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb Vasc Biol. 1994; 14:193-198.
18. Stensvold I, Tverdal A, Urdal P, Graff-Iverson S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle-aged Norwegian women. BMJ. 1993;307:1318-1322.
19. The Lipid Research Clinics Population Studies Data Book: The Prevalence Study. Washington, DC: US Dept of Health and Human Services; 1980. NIH publication 80-1527.
20. Welin L, Eriksson H, Larrsson B, et al. Triglycerides, a major coronary risk factor in elderly men: a study of men born in 1913. Eur Heart J. 1991; 12:700-704.
21. Bengtsson C, Bjorkelund C, Lapidus L, Lissner L. Serum lipid concentrations, obesity, and mortality in women. BMJ. 1993;307:1385-1388.
22. Campbell AJ, Busby WJ, Robertson MC. Over 80 years and no evidence of coronary heart disease: characteristics of a survivor group. J Am Geriatr Soc. 1993;41:1333-1338.
23. Barth JD, Jansen H, Kromhout D, et al. Progression and regression of human coronary atherosclerosis. Atherosclerosis. 1987;68:51-58.
24. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride-and cholesterol-rich lipoproteins have a different effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
25. Blankenhorn DH, Alaupovic P, Wickham E, et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990;81:470-476.
26. Carlson L, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
27. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA. 1984;251:351-364.
28. Frick MH, Elo O, Haada K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia - safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
29. Manninen V, Tenkanen L, Koskinen P. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85: 37-45.
30. Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347: 849-853.
31. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
32. Jukema JW, Bruschke A, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
33. Waters D, Higginson L, Gladstone P, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. Circulation. 1995;92:2404-2410.
34. Denke M. Diet and lifestyle modification and its relationship to atherosclerosis. In: Hunninghake DB, ed. Lipid Disorders. Philadelphia, Pa: WB Saunders Co; 1994:197-224.
35. Schonfeld G. Inherited disorders of lipid transport. In: LaRosa JC, ed. Endocrinology and Metabolism Clinics of North America. Philadelphia, Pa: WB Saunders Co; 1990:229-258.
36. Friedlander Y, Leitersdorf E. Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: results from a segregation analysis in pedigrees with molecularly defined familial hypocholesterolemia. Genet Epidemiol. 1996;13:159-177.
37. Muros M, Rodriguez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4. Atherosclerosis. 1996;121: 13-21.
38. Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, Higashino K. Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia. Ann Rheum Dis. 1995;54:351-354.
39. Ooi TC, Simo IE, Yakichuk JA. Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome. Arterioscler Thromb. 1992;12:1184-1190.
40. Nikkila M, Solakivi T, Lehtimaki T, et al. Postprandial plasma lipoprotein changes in relationship to apolipoprotein E phenotypes and low-density lipoprotein size in men with and without coronary artery disease. Atherosclerosis. 1994; 106:149-157.
41. Razay G, Heaton KW, Bolton CH. Coronary heart disease risk factors in relation to menopause. QJM. 1992;85:889-896.
42. Chaturvedi N, McKeigue PM, Marmot MG. Relationship of glucose intolerance to coronary risk in Afro-Caribbeans compared with Europeans. Diabetologia. 1994;37:765-772.
43. Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med. 1991;90(suppl): 56S-61S.
44. Barrett-Conner E, Witztum JL, Holdbrook M. A community study of high-density lipoproteins in adult non-insulin dependent diabetics. Am J Epidemiol. 1983;117:186-192.
45. Goldschmid MG, Barrett-Conner E, Edelstein SL, et al. Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. Circulation. 1994;89:991-997.
46. LaRosa JC. Metabolic effects of estrogens and progestins. Fertil Steril. 1994;62(suppl):S140-S146.
47. Speroff L, DeCherney A, Burkman RT Jr, et al. Evaluation of a new generation of oral contraceptives. Obstet Gynecol. 1993;81:1034-1047.
48. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular disease. N Engl J Med. 1988;319:1313-1317.
49. Glueck CJ, Scheel D, Fishback J, Steiner D. Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia. Metabolism. 1972;21:657-666.
50. Lobo R. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991;73:925-930.
51. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
52. Griffin B, Farish E, Walsh D, et al. Response of plasma low-density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause. Clin Endocrinol (Oxf). 1993;39: 463-469.
53. Cortellaro T, Nencioni T, Boschetti C, et al. Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment. Eur J Clin Pharmacol. 1991;41:555-559.
54. Haarbo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism. 1991;40:1323-1326.
55. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA. 1995; 273:199-208.
56. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
57. LaRosa JC. Menopause, risk factors, and coronary artery disease. Menopausal Med. 1993;1: 1-5.
58. Howard BV, Hannah JS, Heiser CC, et al. Polyunsaturated fatty acids result in greater cholesterol lowering and less triacylglycerol elevation than do monounsaturated fatty acids in a dose-response comparison in a multi-racial study group. Am J Clin Nutr. 1995;62(suppl):488S-492S.
59. Barnard RJ. Effects of life-style modification on serum lipids. Arch Intern Med. 1991;151:1389-1394.
60. Svendsen OL, Hassager C, Christiansen C, et al. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol. 1996;16:381-385.
61. Warner JG, Brubaker PH, Zhu Y, et al. Long-term (5-year) changes in HDL cholesterol in cardiac rehabilitation patients: do sex differences exist? Circulation. 1995;92:773-777.
62. Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvastatin and niacin on hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med. 1994;96(suppl):64S-68S.
63. LaRosa JC, Applegate W, Grouse J III, et al. Cholesterol lowering in the elderly: results of the Cholesterol Reduction in Senior Program (CRISP) Pilot Study. Arch Intern Med. 1994;154:529-539.
64. Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. In: Hunninghake DB, ed. Lipid Disorders. Philadelphia, Pa: WB Saunders Co; 1994.
65. Nawrocki J, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.